# Renal tumours: Heterogeneity, molecular pathology and biomarkers

**Poster Session 07**

**Location:** Red Area, Room 1 (Level 0)

**Chairs:**
- L. Mengual, Barcelona (ES)
- W. Nakata, Sakai city (JP)
- M. G. B. Tran, Cambridge (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

## State-of-the-art lecture Renal cell cancer heterogeneity

**By:** M. G. B. Tran, Cambridge (GB)

## 75 Germline mutations of renal tumor predisposition genes in early-onset patients

**By:** Wu J.¹, Wang H.¹, Ricketts C.², Linehan M.², Zhu Y.¹, Ye D.¹, Gu C.¹

¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²National Cancer Institute, Dept. of Urology, Bethesda, United States of America

## 76 SETD2-mediated loss of miR-10b determines MAP4K4 activation in renal cell carcinoma

**By:** Yan L., Li H., Zhang Y., Xu H., Ye Z.

Tongji Hospital, Tongji Medical College, Huazhong University of Science Technology, Dept. of Urology, Wuhan, China

## 77 Evaluation of concomitant medication with non-anticancer drugs in patients with surgically treated clear cell renal cell carcinoma: Impact on prognosis, cell-cycle activity, and proliferation

**By:** Rausch S.¹, Neumann E.¹, Klaiber P.¹, Freitag K.¹, Hennenlotter J.¹, Kruck S.¹, Scharpf M.², Fend F.², Schaeffeler E.³, Schwab M.³, Stenzl A.¹, Bedke J.¹

¹Eberhard-Karls-University Tuebingen, Dept. of Urology, Tuebingen, Germany, ²Eberhard-Karls-University Tuebingen, Dept. of Pathology, Tuebingen, Germany, ³Dr. Margarethe Fischer-Bosch-Institute for Clinical Pharmacology, Institute of Clinical Pharmacology (IKP), Stuttgart, Germany

## 78 Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin

**By:** Uemura M.¹, Jingushi K.², Nakano K.¹, Hayashi Y.¹, Wamg C.¹, Ishizuya Y.¹, Yamamoto Y.¹, Matsuzaki K.¹, Hayashi T.¹, Kinouchi T.¹, Kato T.¹, Kawashima A.¹, Ujike T.¹, Nagahara A.¹, Fujita K.¹, Nonomura N.¹
Absolute copy number and fragments size of circulating cell-free DNA are useful markers for renal cell carcinoma

By: Uemura M.1, Yamamoto Y.1, Nakano K.1, Hayashi Y.1, Wang C.1, Ishizuya Y.1, Matsuizaki K.1, Hayashi T.1, Kinouchi T.1, Jingushi K.2, Kato T.1, Kawashima A.1, Nagahara A.1, Fujita K.1, Nonomura N.1

1Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Japan, 2Osaka University Graduate School of Medicine, Dept. of Therapeutic Urologic Oncology, Suita, Japan

The role of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma – a characterization study

By: Reustle A.1, Fisel P.1, Renner O.1, Büttner F.1, Winter S.1, Rausch S.2, Kruck S.2, Nies A.1, Hennenlotter J.2, Scharpf M.3, Fend F.4, Stenzl A.2, Schwab M.1, Schaeffeler E.1, Bedke J.2

1Dr. Margarete Fischer-Bosch Institute, Clinical Pharmacology, Stuttgart, Germany, 2University of Tübingen, Dept. of Urology, Tübingen, Germany, 3University of Tübingen, Dept. of Pathology, Tübingen, Germany, 4University of Tübingen, Dept. of Pathology, Tübingen, Germany

Utility value of the S3-score in metastatic and non-metastatic clear cell renal cell carcinoma for a molecular prediction of clinical outcome

By: Büttner F.1, Winter S.1, Rausch S.2, Hennenlotter J.2, Kruck S.2, Stenzl A.2, Scharpf M.3, Fend F.3, Agaimy A.4, Hartmann A.4, Schwab M.1, Schaeffeler E.1, Bedke J.2

1Dr. Margarete Fischer-Bosch Institute, Dept. of Clinical Pharmacology, Stuttgart, Germany, 2University of Tübingen, Dept. of Urology, Tübingen, Germany, 3University of Tübingen, Dept. of Pathology, Tübingen, Germany, 4Friedrich-Alexander University Erlangen-Nuernberg, Institute of Pathology, Erlangen, Germany

Intra-tumor molecular heterogeneity of clear cell renal cell carcinoma seems to contribute to the diversity of response to targeted therapies

By: Hong B.1, Yang Y.2, Guo S.3, Li Q.3, Gong K.1, Zhang N.2

1Peking University First Hospital, Dept. of Urology, Beijing, China, 2Peking University Cancer Hospital, Dept. of Urology, Beijing, China, 3Crown Bioscience, Division of Translational Oncology, Beijing, China

Plasma microRNA signature - a potential biomarker for differentiating benign from malignant renal lesions

By: Bar El A.1, Greenberg E.2, Baruch Nissim E.2, Markovits E.2, Fridman E.3, Hout Siloni G.4, Pasmanik-Chor M.5, Markel G.2, Ramon J.1
Scientific Programme - EAU18 Copenhagen

84

**Prognostic impact of tumor-infiltrative lymphocytes and circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma**

Nara Medical University, Dept. of Urology, Kashihara, Japan

85

**SLC13A3 as a functional biomarker and determinant of racial discrepancies in renal cell carcinoma**

By: Hennig M., Jordan A., Kramer M., Merseburger A., Soloway M., Lokeshwar V.

1Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Dept. of Urology, Lübeck, Germany, 2University of Miami Miller School of Medicine, David and Sheila Funte Graduate Program in Cancer Biology, Miami, United States of America, 3Memorial Healthcare System, Dept. of Urology, Aventura, United States of America, 4Medical College of Georgia, Augusta University, Biochemistry and Molecular Biology, Augusta, United States of America

**Summary**

M. G. B. Tran, Cambridge (GB)